Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.96 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | GID4 | Q8IVV7 | 3/20 | 0.68 |
| ▸ | KDM1A | O60341 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327233 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL29478499 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL30721685 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL12046710 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL1668148 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL1694774 | 0.98 | PRCP (0.96) | PRCPGAARECQLGID4KDM1A | |
| Hydrochloric Acid SCHEMBL1735508 | 0.98 | GAA (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL1694744 | 0.98 | PRCP (0.96) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL1694844 | 0.98 | PRCP (0.96) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL19610875 | 0.98 | PRCP (0.96) | PRCPGAARECQLGID4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489215-B1 | PROCESS FOR PRODUCING ORGANIC COMPOUND | KANEKA CORP (JP) | 2023-12-20 | — | — | EP | claimed |
| CN-116218804-A | Imine reductase mutant and method for preparing (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline by reduction thereof | 迪嘉药业集团股份有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-116102546-A | Butyrylcholine esterase and monoamine oxidase B dual inhibitor and application thereof | 浙江海洋大学 | 2023-05-12 | — | — | CN | claimed |
| CN-116082232-A | Monoamine oxidase inhibitor, preparation method and application thereof | 浙江海洋大学 | 2023-05-09 | — | — | CN | claimed |
| CN-110407808-B | Novel crystal form of (1S) -1-phenyl-3, 4-dihydro-1H-isoquinoline-2-carbonyl imidazole and preparation method thereof | 燃点(南京)生物医药科技有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-112142663-B | Synthesis method of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline | 中山奕安泰医药科技有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-109689611-B | Method for producing organic compound | 株式会社钟化 | 2021-09-28 | — | — | CN | claimed |
| CN-113200979-A | Synthesis process of solifenacin succinate | 上海予君生物科技发展有限公司 | 2021-08-03 | — | — | CN | claimed |
| CN-110683986-B | Synthesis method of (S) 1-phenyl-1, 2,3, 4-tetrahydroisoquinoline | 中山奕安泰医药科技有限公司 | 2021-03-23 | — | — | CN | claimed |
| CN-212283980-U | (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline synthesis reaction kettle | 济南爱思医药科技有限公司 | 2021-01-05 | — | — | CN | claimed |
| EP-1922308-A2 | PROCESSES FOR OPTICAL RESOLUTION OF 1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE | Teva Pharmaceutical Industries Ltd. (IL) | 2008-05-21 | — | — | EP | claimed |
| US-20080114029-A1 | Polymorphs of solifenacin intermediate | TEVA PHARMACEUTICALS USA, INC. | 2008-05-15 | — | — | US | claimed |
| US-20080091023-A1 | Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline | TEVA PHARMACEUTICALS USA, INC. | 2008-04-17 | — | — | US | claimed |
| WO-2008019057-A2 | POLYMORPHS OF SOLIFENACIN INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-02-14 | — | — | WO | claimed |
| WO-2008019055-A2 | PROCESSES FOR OPTICAL RESOLUTION OF 1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-02-14 | — | — | WO | claimed |
| EP-1879867-A2 | INTERMEDIATES FOR PREPARING SOLIFENACIN | Teva Pharmaceutical Industries Ltd (IL) | 2008-01-23 | — | — | EP | claimed |
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | ASTELLAS PHARMA INC. | 2007-08-09 | — | — | US | claimed |
| US-20070173528-A1 | Process for preparing solifenacin | TEVA PHARMACEUTICALS USA, INC. | 2007-07-26 | — | — | US | claimed |
| WO-2007076116-A2 | INTERMEDIATES FOR PREPARING SOLIFENACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| EP-1757604-A1 | PROCESS FOR PRODUCING SOLIFENACIN OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091023-A1 | Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline | SUCNR1, OPRL1, CHRM1 | PRCP 2196/4885GAA 847/4885RECQL 2194/4885 |
| US-20070173528-A1 | Process for preparing solifenacin | SUCNR1, OPRL1, CHRNG | PRCP 835/4885GAA 511/4885RECQL 3565/4885 |
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | SUCNR1, GLS, CACNA1S | PRCP 1594/4885GAA 270/4885RECQL 1303/4885 |
| US-20080114029-A1 | Polymorphs of solifenacin intermediate | UGT1A1, UBE2V1, OPRL1 | PRCP 1654/4885GAA 2396/4885RECQL 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.